Current oral treatments for erectile dysfunction

REFERENCES

• National Institutes of Health. Impotence. NIH Consensus Statement (1992) 10:1–33.
   Google Scholar
• AYTAQ IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BIU Int. (1999) 84:450–456.
   Google Scholar
• FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. Urol. (1994) 151:54–61.
   Google Scholar
• CHUN J, CARSON CC III: Physician-patient dialogue and clinical evaluation of erectile dysfunction. Urol. Clin. North Am. (2001) 28:249–258.
   PubMed Web of Science ®Google Scholar
• CHEW KK, EARLE CM, STUCKEY BG, JAMROZIK K, KEOGH EJ: Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int. J. Impot. Res. (2000) 12:41–45.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics, Centers for Disease Control and Prevention. Life expectancy at birth by race and sex, 1929-1997. Nat. Vita] Stat. Rep. (1999) 47(28):32.
   Google Scholar
• BRAUN M, WASSMER G, KLOTZ T, REIFENRATH B, MATHERS M, ENGELMANN U: Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey.' Int. J. Impot. Res. (2000) 12:305–311.
   PubMed Web of Science ®Google Scholar
• GIULIANO F, RAMPIN 0: Central neural regulation of penile erection. Neurosci. Biobehav. Rev (2000) 24:517–533.
   PubMed Web of Science ®Google Scholar
• LUITEN PGM, TER HORST GJ, KARST H, STEFFENS AB: The course of paraventricular hypothalamic efferents to autonomic structures in medulla and spinal cord. Brain Res. (1985) 329:374–378.
   PubMedGoogle Scholar
• STEERS WD: Neural pathways and central sites involved in penile erection: neuroanatomy and clinical implications. Neurosci. Biobehav. Rev (2000) 24:507–516.
   PubMed Web of Science ®Google Scholar
• ARGIOLAS A, MELIS MR: Neuromodulation of penile erection: an overview of the role of neurotransmitters and neuropeptides. Frog. Neurobiol (1995) 47:253–255.
   Google Scholar
• BENASSI-BENELLI A, FERRARI F, PELLEGRINI QUARRANTOTTI B: Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch. Int. Pharmacodyn. (1979) 242:241–247.
   PubMedGoogle Scholar
• ANDERSSON K-E, WAGNER G: Physiology of penile erection. Physiol Rev (1995) 75:191–236.
   PubMed Web of Science ®Google Scholar
• SCALETTA LL, HULL EM: Systemic orintracranial apomorphine increases copulation in long-term castrated male rats. Pharmacol Biochem. Behav. (1990) 37:471–475.
   PubMedGoogle Scholar
• MELIS MR, STANCAMPIANO R, ARGIOLAS A: Hippocampal oxytocin mediates apomorphine-induced penile erection and yawning. Pharmacol Biochem. Behav. (1992) 42:61–66.
   PubMedGoogle Scholar
• CHUANG AT, STEERS WD: Neurophysiology of penile erection. In Textbook of Erectile Dysfunction. Carson CC, Kirby RS, Goldstein I (Eds). Isis Medical Media, Oxford, UK (1999):59–72.
   Google Scholar
• MARSON LAND MCKENNA KE: A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes. Exp. Brain Res. (1992) 88:313–320.
   PubMedGoogle Scholar
• FINBERG JP, VARDI Y: Inhibitory effectof 5-hydroxytryptamine on penile erectile function in the rat. Br. .1. Pharmacol (1990)101:698–702.
   PubMedGoogle Scholar
• BANCILA M, VERGE D, RAMPIN 0 et al.: 5-Hydroxytryptamine 2c receptors on spinal neurons controlling penile erection in the rat. Neuroscience (1999)92:1523–1537.
   Google Scholar
• HEDLUND P, NY L, ALM P, ANDERSSON KE: Cholinergic nerves in human corpus cavernosum and spongiosum contain nitric oxide synthase and heme oxygenase. Um]. (2000) 164:868–875.
   Google Scholar
• CELLEK S, MONCADA 5: Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: a comparison with other species. Proc. Natl. Acad. Sd. USA (1997) 94:8226–8231.
   PubMed Web of Science ®Google Scholar
• NITAHARA KS, LUE TF: Microscopic anatomy of the penis. In: Textbook of Erectile Dysfunction. Carson CC, Kirby RS, Goldstein I (Eds). Isis Medical Media, Oxford, UK (1999):31–41.
   Google Scholar
• SCHMIDT HH, LOHMAN SM, WALTER U: The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochem. Biophys. Acta (1993) 1178:153–175.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, TURKO IV, CORBIN JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Frog. Nucleic Acid Res. MM. Biol. (2001) 65:1–52.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, LINCOLN TM, CORBIN JD: Characterization of a novel cGMP binding protein from rat lung. Biol. Chem. (1980) 255:620–626.
   Google Scholar
• BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. Um]. (1998) 159:2164–2171.
   Google Scholar
• LINCOLN TM: Cyclic GMP and mechanisms of vasodilatation. Pharmacol. Ther. (1989) 41:479–502.
   PubMed Web of Science ®Google Scholar
• LINCOLN TM, CORN WELL TL: Intracellular cyclic GMP receptor proteins. FASEB J. (1993) 7:328–338.
   PubMed Web of Science ®Google Scholar
• CLAPP LH, GURNEY AM: Modulation of calcium movements by nitroprusside in isolated smooth muscle cells. Plugers Arch. (1991) 418:462–470.
   PubMed Web of Science ®Google Scholar
• ARCHER SL, HUANG JM, HAMPL V, NELSON DP, SHULTZ PJ, WEIR EK: Nitric oxide and cGMP cause vasodilation by activation of a charydotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA (1994) 91:7583–7587.
   PubMed Web of Science ®Google Scholar
• FURUKAWA K, OHSHIMA N, TAWADA INATA Y, SHIGKAWA M: Cyclic GMP stimulates Na+/Ca2+ exchange in vascular smooth muscle cells in primary culture. Biol. Chem. (1991) 266:12337–12341.
   Google Scholar
• YOSHIDA Y, SUN HT, CAI JQ, IMAI S: Cyclic GMP-dependent protein kinase stimulates the plasma membrane Ca2+ pump ATPase of vascular smooth muscle via phosphorylation of a 240-kDa protein. J. Biol. Chem. (1991) 266:19819–19825.
   PubMedGoogle Scholar
• KOMALAVILAS P, LINCOLN TM: Phosphorylation of the inositol 1,4,5-triphosphosphate receptor by cyclic GMP-dependent protein kinase. I Biol. Chem. (1994) 269:8701–8707.
   Google Scholar
• CORN WELL TL, PRYZWANSKY KB, WYATT TA, LINCOLN TM: Regulation of sarcoplasmic reticulum protein dephosphorylation by localised cyclic GMP dependent protein kinase in vascular smooth muscle cells. MM. Pharmacol (1991) 40:923–931.
   PubMedGoogle Scholar
• SCHLOSSMANN J, AMMENDOLA A, ASHMAN K, ZONG X, HUBER A, NEUBAUER G et al.: Regulation of intracellular calcium by a signalling complex of IRAG, IP3 receptor and cGMP kinase Nature (2000) 404(6774):197–201.
   Google Scholar
• HIRATA M, KOHSE KP, CHANG CH, IKEBE T, MURAD F: Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. " Biol. Chem. (1990) 265:1268–1273.
   PubMed Web of Science ®Google Scholar
• OSTERLOH I, EARDLEY I, CARSON C, PADMA-NATHAN H: Sildenafil: a selective phosphodiesterase (PDE) 5 inhibitor in the treatment of erectile dysfunction (ED). In: Textbook of Erectile Dysfunction. Carson CC, Kirby RS, Goldstein I (Eds) Isis Medical Media, Oxford, UK (1999):285–308.
   Google Scholar
• BERRIDGE MJ: Inositol trisphosphate and calcium signalling. Nature (1993) 361:315–325.
   PubMed Web of Science ®Google Scholar
• HOLMQUIST F, KIRKEBY HJ, LARSSON B, FORMAN A, ALM P, ANDERSSON KE: Functional effects, binding sites and immunolocalization of endothelin-1 in isolated penile tissues from man and rabbit." Pharmacol Exp. The]: (1992) 261:795–802.
   Google Scholar
• COMITER CV, SULLIVAN MP, YALLA SV, KIFOR I: Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: in vitro studies in canines. Int. J. Impot. Res. (1997) 9:135–140.
   PubMedGoogle Scholar
• BORNMAN MS, DORMEHL IC, FRANZ RC, DU PLESSIS DJ, JACOBS DJ: Platelets and thromboxane A2 in the pathogenesis of aging penile vascular changes and impotence. Arch. Andra (1986) 17:233–234.
   PubMed Web of Science ®Google Scholar
• WALLIS RM: The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) Type 5. Nippon Yakurigaku Zasshi (1999) 114\(Suppl. 1):22P–26P.
   Google Scholar
• CHUANG AT, STRAUSS JD, MURPHY RA, STEERS WD: Sildenafil, a Type 5 cGMP phosphodiesterase inhibitor specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J. Urol. (1998) 160:257–261.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl. J. Med. (1998) 338:1397–1404.
   PubMed Web of Science ®Google Scholar
• PRICE DE, GINGELL JC, GEPI-ATTEE S, WAREHAM K, YATES P, BOOLELL M: Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet. Med. (1998) 15:821–825.
   PubMedGoogle Scholar
• DINSM ORE WW, HODGES M, HARGREAVES C, OSTERLOH IH, SMITH MD, ROSEN RC: Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urol. (1999) 53:800–805.
   PubMedGoogle Scholar
• RENDELL MS, RAJFERJ, WICKER PA, SMITH MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA (1999) 281:421–426.
   PubMed Web of Science ®Google Scholar
• WEBER DC, BIERI S, KURTZ JM, MIRALBELL R: Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J. Clin. Oncol (1999) 17:3444–3449.
   PubMedGoogle Scholar
• HULTLING C, GIULIANO F, QUIRK F, PENA B, MISHRA A, SMITH MD: Quality of life in patients with spinal cord injury receiving Viagra (sildenafil citrate) for the treatment of erectile dysfunction. Spinal Cord (2000) 38:363–370.
   PubMed Web of Science ®Google Scholar
• McMAHON CG, SAMALI R, JOHNSON H: Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. Urol. (2000) 64:1192–1196.
   Google Scholar
• HUSSAIN IF, BRADY CM, SWINN MJ, MATHIAS CJ, FOWLER CJ: Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. I Neuro/. Neurosurg. Psychiatry (2001) 71:371–374.
   PubMed Web of Science ®Google Scholar
• OLSSON AM, PERSSON CA: Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int. J. Clin. Pract. (2001) 55:171–176.
   PubMed Web of Science ®Google Scholar
• WAGNER G, MONTORSI F, AUERBACH S, COLLINS M: Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. Cerontol A. Biol. Sci. Med. Sci. (2001) 56:M113–M119.
   Google Scholar
• LEWIS R, BENNETT CJ, BORKON WD et al.: Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Viol (2001) 57:960–965.
   Google Scholar
• MEULEMAN E, CUZIN B, OPSOMER RJ et al.: A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int. (2001) 87:75–81.
   PubMed Web of Science ®Google Scholar
• BLANDER DS, SANCHEZ-ORTIZ RE WEIN AJ, BRODERICK GA: Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int. .1. Impot. Res. (2000) 12:165–168.
   PubMed Web of Science ®Google Scholar
• HATZICHRISTOU DG: Sildenafil citrate: lessons learned from 3 years of clinical experience. Int. J. Impot. Res. (2002) 14\(Suppl. 1):S43–S52.
   Google Scholar
• MUNEER A, KALSI J, KELL P, MINHAS S: Aetiological factors associated with failure of treatment with sildenafil and outcome. hat. Impot. Res. (2002) 14\(Suppl. 3):553.
   Google Scholar
• CELLEK S, RODRIGO JA, LOBOS E, FERNANDEZ P, SERRANO J, MONCADA S: Selective nitrergic neurodegeneration in diabetes mellitus, a nitric oxide-dependent phenomenon. Br. Pharmacy]. (1999) 128:1804–1812.
   PubMed Web of Science ®Google Scholar
• SHABSIGH R, PADMA-NATHAN H, GITTLEMAN M, MCMURRAY J, KAUFMAN J, GOLDSTEIN I: Intracavernosal alprostadil alfadex (EDEXNIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Viol (2000) 55:477–480.
   Google Scholar
• GUTIERREZ P, HERNANDEZ P, JIMENEZ A, MAS M: Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. hat. Impat. Res. (2002) 14\(Suppl. 3):537.
   Google Scholar
• DMITRIEV DG, GAMIDOV SI, OVCHINNIKOV RI, MAZO EB, TIRSI KA: Advantages of combining of sildenafil and alprostadil taken by nonrespondents to monotherapy of erectile dysfunction. Int. Impat. Res. (2002) 14\(Suppl. 3):586.
   Google Scholar
• LIM PH, LI MK, NG FC et al.: Clinicalefficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. Int. J. Ural (2002) 9:308–315.
   PubMed Web of Science ®Google Scholar
• FAGELMAN E, FAGELMAN A, SHABSIGH R: Efficacy, safety, and use of sildenafil in urologic practice. Ural (2001) 57:1141–1144.
   Google Scholar
• GABRIELI CB, REGINE F, VINGOLO EM, RISPOLI E, FABBRI A, ISIDORI A: Subjective visual halos after sildenafil (Viagra) administration: Electroretinographic evaluation. Ophthalmol. (2001) 108:877–881.
   PubMedGoogle Scholar
• WEBB DJ, MUIRHEAD GJ, WULFF M, SUTTON JA, LEVI R, DINSMORE WW: Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. I Jim. Coll. Cardiol. (2000) 36:25–31.
   PubMed Web of Science ®Google Scholar
• JACKSON G, KELTAI M, GILLIES H, CZORNIAK M, KEATING Z: Viagra is well tolerated by subjects with stable angina and erectile dysfunction during incremental treadmill exercise. Lim Urol. Sapp]. (2002) 1:596P
   Google Scholar
• LIM PH, MOORTHY P, BENTON KG: The clinical safety of viagra. Ann. NY Acad. Sci. (2002) 962:378–388.
   PubMed Web of Science ®Google Scholar
• ANGULO J, GADAU M, FERNANADEZA, GABANCHO S, CUEVAS P, MARTINS T: Tadalafil enhances nitric-oxide mediated relaxation of human arterial and trabecular penile smooth muscle. The European Association for the Study of Diabetes (EASD), Glasgow Scotland 2001.
   Google Scholar
• PATTERSON B, BEDDING A, JEWELL H, PAYNE C, MITCHELL M: Dose-normalised pharmacokinetics of Tadalafil administered as a single dose to healthy volunteers. Eat Urol. Sapp]. (2002) 1:600P.
   Google Scholar
• BROCK GB, McMAHON CG, CHEN KK et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. Urol (2002) 168:1332–1336.
   Google Scholar
• SAENZ DE TEJADA I, EMMICK J, ANGLIN G, FREDLUND P, PULLMAN W: The effect of as needed Tadalafil (IC351) on erectile dysfunction in men with diabetes. Int. Impot. Res. (2001) 13 (Suppl. 4):546.
   Google Scholar
• KLONER R: Cardiovascular profile of tadalafil, a new PDE5 inhibitor. .1 Urol (2002) 167\(Suppl. 4):P707.
   Google Scholar
• KIM NN, HUANG YH, GOLDSTEIN I, BISCHOFF E, TRAIS AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel selective phosphodiesterase Type 5 inhibitor. Life Sci. (2001) 69:2249–2256.
   PubMed Web of Science ®Google Scholar
• CHOI S, O'CONNELL L, MIN K, MUNARRIZ R, GOLDSTEIN I, BISCHOFF E et al.: Comparison between vardenafil and sildenafil in facilitating pelvic nerve-mediated penile erection in a rabbit model. Int. Impot. Res. (2001) 13\(Suppl. 4):516.
   Google Scholar
• SAENZ DE TEJADA I, ANGULO J, CUE VAS P et al.: The phosphodiesterase inhibitory selectivity and the M vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int. I Impot. Res. (2001)13:282–290.
   Google Scholar
• STARK S, SACHSE R, LIEDL T, HENSEN J, ROHDE G, WENSING G: Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Lim Urol. (2001) 40:181–190.
   Google Scholar
• KLOTZ T, SACHSE R, HEIDRIH A, JOCKENHOVEL F, ROHDE G, WENSING G et al.: Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World j Urol. (2001) 19:32–39.
   PubMed Web of Science ®Google Scholar
• PORST H, ROSEN R, PADMA-NATHAN H et al: The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase Type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. Impot. Res. (2001) 13:192–199.
   PubMed Web of Science ®Google Scholar
• PORST H, PADMA-NATHAN H, THIBONNIER M, EARDLEY I: Efficacy and safety of vardenafil, a selective Phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy Lim Urol. Sapp]. (2002) 1:599P
   Google Scholar
• BROCK G, TAYLOR T, SEGER M: Efficacy and tolerability of vardenafil in males with erectile dysfunction following radical prostatectomy. Eat Urol. Sapp]. (2002) 1:598P
   Google Scholar
• PRYOR J: Vardenafil: update on clinical experience. Int. Impot. Res. (2002) 14\(Suppl. 1):565–569.
   Google Scholar
• THADANI U, MAZZU A: Exercise-induced ischaemia was not adversely affected by vardenafil during an exercise stress test in men with coronary artery disease. Eat Urol. Sapp]. (2002) 1:595P.
   Google Scholar
• CORBIN JD, FRANCIS SH: Pharmacology of phosphodiesterase-5 inhibitors. Int.j Clin. Pract. (2002) 56:453–459.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, STIEF CG, MACHTENS S,SCHULTHEISS D, HARTMANN U, TRUSS MC et al.: Oral phentolamine as treatment for erectile dysfunction. Urol. (1998) 159:1214–1216.
   Google Scholar
• GOLDSTEIN I: Oral phentolamine: an a-1, a-2 adrenergic antagonist for the treatment of erectile dysfunction. Int. Impot. Res. (2000) 12 (Suppl. 1):575–580.
   Google Scholar
• GOLDSTEIN I, CARSON C, ROSEN R, ISLAM A: Vasomax for the treatment of male erectile dysfunction. World J. Urol. (2001) 19:51–56.
   PubMedGoogle Scholar
• HOFFMAN BB, LEFKOWITZ RJ: a-adrenergic receptor subtypes. N Engl. Med. (1980) 302:1390–1396.
   PubMed Web of Science ®Google Scholar
• GOLDBERG MR, ROBERTSON D: Yohimbine: a pharmacological probe for study of the a2-adrenoreceptor. Pharmacol. Rev (1983) 35:143–180.
   PubMed Web of Science ®Google Scholar
• MORALES A: Yohimbine in erectile dysfunction: the facts. Int. .1. Impot. Res. (2000) 12\(Suppl. 1):570–574.
   Google Scholar
• RILEY AJ, GOODMAN RE, KELLETT JM, ORR R: Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sexual and Marital Therapy (1989) 4:17–26.
   Google Scholar
• ERNST E, PITTLER MH: Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. Urol. (1998) 159:433–436.
   Google Scholar
• O'BRIEN AAJ, BULPITT CJ: Hypertensive disease. In: Avery's Drug Treatment (4th edit). Speight TM, Holford HG (Eds), Blackwell Science, Auckland, New Zealand (1997):906.
   Google Scholar
• PETERSON CA, BENNETT AH, HELLSTROM WJ et al.: Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. Urol. (1998)159:1523–1528.
   Google Scholar
• DE ROSE AF, CARMIGNANI G, CORBU C, GIGLIO M, TRAVERSO P, NASELLI A et al.: Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol. mt. (2002) 68:95–98.
   Google Scholar
• DE ROSE AF, GIGLIO M, TRAVERSO P, LANTIERI P, CARMIGNANI G: Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int. Impot. Res. (2002) 14:50–53.
   PubMed Web of Science ®Google Scholar
• VAIDYANATHAN S, SONI BM, SINGH G, SETT P, KRISHNAN KR: Prolonged penile erection association with terazosin in a cervical spinal cord injury patient. Spinal Cord (1998) 36:805.
   PubMedGoogle Scholar
• TRAISH A, KIM NN, MORELAND RB, GOLDSTEIN I: Role of a adrenergic receptors in erectile function. Int. J. Impot. Res. (2000) 12\(Suppl. 1):S48–S63.
   Google Scholar
• MEINHARDT W, SCHMITZ PI, KROPMAN RF et al.: Trazodone, a double blind trial for treatment of erectile dysfunction. Int. I Impot. Res. (1997) 9:163–165.
   PubMed Web of Science ®Google Scholar
• ENZLIN P, VANDERSCHUEREN D, BONTE L, VANDERBORGHT W, DECLERCQ G, DEMYTTENAERE K: Trazodone: a double-blind, placebo-controlled, randomized study of its effects in patients with erectile dysfunction without major organic findings. Int. I Impot. Res. (2000) 12:223–228.
   PubMed Web of Science ®Google Scholar
• LAL S: Apomorphine in the evaluation of dopaminergic function in man. Frog. Neuropsychopharmacol Biol. Psychiatry (1988) 12:117–164.
   PubMed Web of Science ®Google Scholar
• CHEN KK, CHAN SH, CHANG LS: Dopaminergic neurotransmission at the paraventricular nucleus of hypothalamus in central regulation of penile erection in the rat. J. Urol. (1999) 162:237–242.
   PubMed Web of Science ®Google Scholar
• BENASSI-BENELLI A, FERARI F, PELLEGRINI QUARRANTOTTI B: Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats. Arch. Int. Pharmacodyn. (1979) 242:241–247.
   PubMedGoogle Scholar
• HEATON JP, VARRIN S: Metoclopramide decreases apomorphine-induced yawning and penile erection. Pharmacol Biochem. Behav. (1991) 38:917–920.
   PubMed Web of Science ®Google Scholar
• VALLONE D, PICETTI R, BORRELLI E: Structure and function of dopamine receptors. Neurosci. Bibehav. Rev (2000) 24:125–132.
   PubMed Web of Science ®Google Scholar
• GIULIANO FA, ALLARD J, RAMPIN 0, DROUPY S, ALEXANDRE L, BERNABE, J: Spinal proerectile effect of apomorphine in the anesthetized rat. Int. I Impot. Res. (2001) 13:110–115.
   PubMedGoogle Scholar
• SEAGRAVES RT, BARI M, SEAGRAVES K, SPIRNA P: Effect of apomorphine on penile tumescence in men with psychogenic impotence. Urol. (1991) 145:1174–1175.
   Google Scholar
• DULA E, BUKOFZER S, PERDOK R, GEORGE M: Double-blind, cross-over comparison of 3 mg apomorphine SL with placebo and 4 mg apomorphine SL in male erectile dysfunction. Ear: Urol. (2001) 39:558–564.
   PubMed Web of Science ®Google Scholar
• HEATON JP: Characterizing the benefit of apomorphine SL (Uprima) as an optimized treatment for representative populations with erectile dysfunction. Int. I Impot. Res. (2001) 13\(Suppl. 3):535–539.
   Google Scholar
• MIRONE VG, STIEF CG: Efficacy of apomorphine SL in erectile dysfunction. BIU Int (2001) 889\(Suppl. 30):25–29.
   Google Scholar
• HEATON JPW, SLEEP, DJ, PERDOK RJ, PADLEY RJ: Uprima success increased with consecutive administrations. Int. I Impot. Rev. (2002) 14\(Supp1.3):S21
   Google Scholar
• MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLADEMOROS F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry (2001) 62\(Suppl. 3):10–21.
   Google Scholar
• KEENE LC, DAVIES PH: Drug-related erectile dysfunction. Adverse Drug React. Toxicol Rev (1999)18:5–24.
   PubMedGoogle Scholar
• HEATON JPW, SLEEP DJ, PERDOK R, RESCEK ME: Apomorphine SL 2mg and 3mg is well tolerated and effective in men with ED concurrently taking antidepressant medication. Ear: Urol. Stipp] (2002) 1:602P.
   Google Scholar
• SOMLYO AP, SOMLYO AV: Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physic] (2000) 522:177–185.
   Google Scholar
• REES RW, RALPH DJ, ROYLE M, MONCADA S, CELLEK 5: Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br. J. Pharmacol (2001) 133:455–458.
   PubMed Web of Science ®Google Scholar
• CHITALEY K, WINGARD CJ, VVEBB RC et al.: Antagonism of rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. (2001) 7:119–122
   PubMed Web of Science ®Google Scholar
• CELLEK S, MONCADA S: Nitrergic neurotransmission in the physiology of penile erection and pathophysiology of erectile dysfunction. In: Nitric Oxide and the Peripheral Nervous System. Toda N, Moncada S, Furchgott R, Higgs EA. Portland Press, London, UK (2000):61.
   Google Scholar
• FRIEBE A, KOESLING D: Mechanism of YC-1 induced activation of soluble guanylyl cyclase. Mol. Pharmacol (1998) 53:123–127.
   PubMed Web of Science ®Google Scholar
• VVEGENERJW, GATH I, FORSTERMANN U, NAWRATH H: Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat. Br. J. Pharmacol (1997) 122:1523–1529.
   PubMedGoogle Scholar
• LIU SP, GUH JH, TENG CM, LAI MK, HSIEH JT: YC-1, a NO-independent guanylate cyclase stimulator, relaxes rabbit cavernous smooth muscle via increasing intracellular cyclic GMP Int. I Impot. Rev. (2000) 12\(Suppl. 2):518.
   Google Scholar
• MIZUSAWA H, HEDLUND P, BRIONI JD, SULLIVAN JP, ANDERSSON KE: Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. (2002) 167:2276–2281.
   PubMed Web of Science ®Google Scholar
• NAKANE M, HSIEH G, MILLER LN et al.: Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int. J. Impot. Res. (2002) 14:121–127.
   PubMed Web of Science ®Google Scholar
• HSEIH GC, O'NEILL AB, NAKONE M, MORELAND RS, BRIONI JD: YC-1, a soluble guanylate cyclase activator potentiates the NO/cGMP pathway and facilitates penile erection in rats.Urol.(2002) 167\(Suppl. 4):939.
   Google Scholar
• GALLE J, ZABEL U, HUBNER U, HATZELMANN A, WAGNER B, WANNER C et al.: Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol (1999) 127:195–203.
   PubMed Web of Science ®Google Scholar
• WOHLFART P, MALINSKI T, RUETTEN H et al: Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. Pharmacol (1999) 128:1316–1322.
   PubMed Web of Science ®Google Scholar
• MORELAND RB, HSEIH GC, NAKONE M et al.: Novel soluble guanylate cyclase activators A-344905 and A-350619 activate sGC M vitro and facilitate erection in rats. Urol. (2002) 167\(Suppl. 4):938.
   Google Scholar
• BISCHOFF E, SCHRAMM M, STRAUB A, FEURER A, STASCH JP: BAY41-2272 a stimulator of soluble guanylyl cyclase induces NO-dependent penile erection in vivo. (2002) Int. I Impot. Res. 14\(Suppl. 3):543.
   Google Scholar
• KALSI JS, REES RW, HOBBS AJ, et al.: BAY41-2272 a novel NO-independent soluble guanylate cyclase inhibitor relaxes human and rabbit corpus cavernosum. Int. Impot. Res. 14\(Suppl. 3):52.
   Google Scholar